Mathieu Coscarella

Mathieu Coscarella

Auto-generated profile, based on publicly available information

Mathieu Coscarella

CHU Saint-Pierre/Universite Libre de Bruxelles (ULB)

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2018 in Therapeutic Advances in Urology
Verified
Journal Article
Open access
MCMathieu Coscarella
Mathieu Coscarella
SMSerge Motte
Serge Motte
MDMohamad-Fadi Dalati
Mohamad-Fadi Dalati
TOTania Oliveira-E-Silva
Tania Oliveira-E-Silva
KEKim Entezari
Kim Entezari
TRThierry Roumeguere
Thierry Roumeguere
Background: Prostate biopsy is a rather frequent procedure, mostly performed in outpatient settings. Bleeding complications following this procedure require precise and delicate management of pre-, peri- and post-procedure anti-coagulation treatments. New oral anti-coagulation drugs (NOACs) are increasingly used. However, the management of such treatments is feared and not yet well known to urologists. A protocol for prostate biopsy management of NOACs seems mandatory. Materials and methods: A review of the literature, using Pubmed and Cochrane databases, together with analysis of several medical associations’ recommendations in urology, anaesthesiology, cardiology, oncology and drug safety agency, was performed. Results: There are no recommendations about NOAC management for prostate biopsy available from scientific societies. There is also a lack of specific urological studies. However, several panels of expert recommendations could be helpful in establishing standardized protocols adapted from surgery to prostate biopsy. With the growing use of NOACs, recommendations have shifted to continue anti-coagulant treatment without bridging NOACs for low bleeding risk procedures such as prostate biopsy, in carefully selected groups of patients. Conclusion: Extensive indications coupled with the ease of use of NOACs contribute significantly to the widespread replacement of traditional vitamin K antagonist. Knowing that heparin bridging leads to more bleeding, and in the pursuit of more autonomy and safety, urologists should be able to propose dedicated anti-coagulant management using NOACs adapted to carefully selected patients before the prostate biopsy procedure. Further studies and guidelines specific to the concept of non-bridging for anti-coagulant-requiring patients are mandatory for this routine procedure.

28 July 2023 in Radiology Case Reports
Verified
Journal Article
Open access
MBMoncef Al Barajraji
Moncef Al Barajraji
MCMathieu Coscarella
Mathieu Coscarella
SHSerge Holz
Serge Holz
IMIlan Moussa
Ilan Moussa
MNMichel Naudin
Michel Naudin
NBNicolas Brassart
Nicolas Brassart
Renal artery pseudoaneurysm may develop after laser flexible ureteroscopy stone lithotripsy (FURSL). Typical symptoms include flank pain, persistent hematuria, delayed refractory anemia, or hemorrhagic shock in case of pseudoaneurysm rupture. This complication of laser FURSL is very rare with only five cases reported in the literature as of April 2023, of which one involved Thulium laser. We report the case of a 65-year-old man with recurrent renal lithiasis who underwent FURSL using Thulium fibered laser (TFL) for 8 mm stone of left kidney upper pole. Persistent hematuria developed postoperatively, secondary to a pseudoaneurysm from a segmental branch of the left renal artery. It was diagnosed on arteriography performed for sudden hemorrhagic shock 27 days after surgery. Selective embolization with metallic micro-coils resolved hematuria. Although laser FURSL is often uncomplicated and TFL is regarded as safe, this complication should be suspected when refractory hematuria or hemodynamic instability follows the procedure. We report this case to add support to the current literature and outline procedural risk factors and useful precautions during the procedure.

1 July 2015 in Progrès en Urologie
Verified
Journal Article
Closed access
MCM. Coscarella
M. Coscarella
LVL. Viart
L. Viart
PNP. Nguyen
P. Nguyen
FSF. Saint
F. Saint

25 September 2025 in Life
Verified
Journal Article
Open access
PDF file
MBMoncef Al Barajraji
Moncef Al Barajraji
MCMathieu Coscarella
Mathieu Coscarella
ISIlyas Svistakov
Ilyas Svistakov
HSHelena Margot Flôres Soares da Silva
Helena Margot Flôres Soares da Silva
PDPaula Mata Déniz
Paula Mata Déniz
JMJesús Moreno-Sierra
Jesús Moreno-Sierra
Prostate cancer (PCa) diagnosis has historically relied on the prostate-specific antigen (PSA) testing. Although the screening significantly reduces mortality rates, PSA has low specificity with risks of overdiagnosis and overtreatment. These limitations highlight the need for a more accurate diagnostic approach. Emerging technologies, such as artificial intelligence (AI), novel biomarkers, and advanced imaging techniques, offer promising avenues to enhance the accuracy and efficiency of PCa diagnosis and risk stratification. This narrative review comprehensively analyzed the current literature, focusing on new tools aiding PCa diagnosis (AI-driven image interpretation, radiomics, genomic classifiers, biomarkers, and multimodal data integration) with consideration for technical, regulatory, and ethical challenges related to clinical implementation of AI-based technologies. A literature search was performed using the PubMed and MEDLINE databases to identify relevant peer-reviewed articles published in English using the search terms “prostate cancer,” “artificial intelligence,” “machine learning,” “deep learning,” “MRI,” “histopathology,” and “diagnosis.” Articles were selected based on their relevance to AI-assisted diagnostic tools, clinical utility, and performance metrics. In addition, a separate section was developed initially to contextualize the limitations of current PSA-based screening approaches. The reviewed studies showed that AI had significant utility in prostate mpMRI interpretation (lesion detection; Gleason grading) with high accuracy and high reproducibility. For the pathologist, AI-driven algorithms improve the diagnostic accuracy of digital slide evaluation for histologic diagnosis of prostate cancer and automated Gleason score grading. Genomic tools such as the Oncotype DX test, combined with AI, could also allow for tailored and individualized risk prediction. Overall, multimodal models integrating clinical, imaging, and molecular data often outperform traditional PSA-based strategies and reduce unnecessary biopsies. Transition from PSA-centered toward AI-driven, biomarker-supported, and image-enhanced diagnosis marks a critical evolution in PCa diagnosis.

9 March 2024 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MCMathieu Coscarella
Mathieu Coscarella
MBMoncef Al Barajraji
Moncef Al Barajraji
IMIlan Moussa
Ilan Moussa
LHLeslie Hombert
Leslie Hombert
MNMichel Naudin
Michel Naudin
TRThierry Roumeguère
Thierry Roumeguère

15 May 2025 in The French Journal of Urology
Verified
Journal Article
Closed access
HCHugo Carissimo
Hugo Carissimo
MCMathieu Coscarella
Mathieu Coscarella
MBMoncef Al Barajraji
Moncef Al Barajraji
IMIlan Moussa
Ilan Moussa
BMBenoit Malval
Benoit Malval